Go Deep
Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,583 | -0.1 | 0.39 | 0.03 | 20.17 |
| Oct 2026 | 23,607 | -0.1 | 0.36 | 0.03 | 18.94 |
| Oct 2026 | 21,801 | -0.1 | 0.37 | 0.03 | 19.26 |
| Oct 2026 | 21,811 | -0.1 | 0.36 | 0.03 | 18.75 |
| Oct 2026 | 21,819 | -0.1 | 0.35 | 0.03 | 18.31 |
| Oct 2026 | 21,831 | -0.1 | 0.34 | 0.03 | 17.65 |
Vistagen Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,476,000.0 | 465,000.0 | 303,000.0 | 258,000.0 |
| Net Profit | -13,030,000.0 | -16,274,000.0 | -18,899,000.0 | -19,417,000.0 |
| EPS | -0.3 | — | -0.5 | -0.5 |
Vistagen Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 1,269,000.0 | 486,000.0 | 1,064,000.0 | -227,000.0 | — |
| Net Profit | -69,685,000.0 | -51,418,000.0 | -29,362,000.0 | -59,248,000.0 | — |
| EPS | -1.8 | -1.7 | -1.5 | -8.5 | — |
Vistagen Therapeutics, Inc. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 48,564,000.0 | 84,341,000.0 | 123,653,000.0 | 21,089,000.0 | — |
| Total Liabilities | 13,044,000.0 | 13,951,000.0 | 9,367,000.0 | 9,009,000.0 | — |
| Total Equity | 35,520,000.0 | 70,390,000.0 | 114,286,000.0 | 12,080,000.0 | — |
Owes vs Owns
Vistagen Therapeutics, Inc. owed $0.31 for every $1 it owned in Jun 2026, down from $0.43 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.31× | 0.27× | 0.17× | 0.08× | 0.43× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Vistagen Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Mar 2026
Cash & short-term investments 93.5%Fixed assets (tangible) 2.5%Other assets 4.0%
How it's funded — Mar 2026
Long-term debt 0.5%Payables 3.2%Other liabilities 23.0%Shareholders' equity 73.1%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 45.4 | 80.5 | 119.2 | 16.6 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.8 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.2 | 1.8 | 2.3 | 2.8 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.9 | 2.0 | 2.2 | 0.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.1 | 0.6 | 0.6 | 0.1 |
| Long-term debt | 0.2 | 0.9 | 1.6 | 2.1 |
| Payables | 1.5 | 0.7 | 1.5 | 2.5 |
| Other liabilities | 11.2 | 11.8 | 5.7 | 4.3 |
| Shareholders' equity | 35.5 | 70.4 | 114.3 | 12.1 |
| Net tangible assets | 35.5 | 70.4 | 114.3 | 12.1 |
Vistagen Therapeutics, Inc. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -66,436,000.0 | -42,097,000.0 | -25,813,000.0 | -49,716,000.0 | — |
| Investing Activities | -877,000.0 | -13,148,000.0 | -61,000.0 | -740,000.0 | — |
| Financing Activities | 30,971,000.0 | 3,210,000.0 | 128,402,000.0 | -1,041,000.0 | — |